Ocular Therapeutix Q2 2026 Earnings Report

Ocular Therapeutix EPS Results

• Actual EPS: -$0.35
• Consensus EPS: -$0.40
• Beat/Miss: Beat by +$0.05
• One Year Ago EPS: -$0.39

Ocular Therapeutix Revenue Results

• Actual Revenue: $13.48 million
• Expected Revenue: $13.20 million
• Beat/Miss: Beat by +$274.00 thousand
• YoY Revenue Growth: -0.10%

Ocular Therapeutix Announcement Details

• Quarter: Q2 2026
• Date: 8/3/2026
• Time: Before Market Opens
• Conference Call Date: Monday, August 3, 2026
• Conference Call Time: 7:00AM ET

Ocular Therapeutix (NASDAQ:OCUL) is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S. Food and Drug Administration for the treatment of ocular inflammation following ophthalmic surgery. Ocular Therapeutix also markets ReSure® Sealant, a synthetic polyethylene glycol-based hydrogel approved to seal corneal incisions and reduce postoperative fluid egress. These products exemplify the company’s strategy of combining novel delivery systems with established drug compounds to enhance safety and efficacy.

In addition to its marketed therapies, Ocular Therapeutix maintains a pipeline of investigational candidates targeting conditions such as glaucoma and dry eye disease. Key programs include OTX-TKI, a tyrosine kinase inhibitor insert under development for glaucoma, and OTX-DED, an insert incorporating low-dose dexamethasone for chronic dry eye. The company leverages partnerships and licensing agreements to expand its technology platform and advance clinical programs.

Led by Chief Executive Officer Antony Mattessich, Ocular Therapeutix operates manufacturing and research facilities in the United States and collaborates with contractors and distributors to support commercialization. The company’s management team combines expertise in ophthalmology, drug delivery, and regulatory affairs to guide product approvals and market access strategies within the U.S. and select international markets.